Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression

Cancer Epidemiology Biomarkers and Prevention

Volumn 12, Issue 1, 2003, Pages 23-27

  Xu, Yue ^a   Shibata, Atsuko ^a   McNeal, John E ^a   Stamey, Thomas A ^a   Feldman, David ^a   Peehl, Donna M ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CYTOSINE; DNA; ENDONUCLEASE; ENDONUCLEASE FOKI; PROSTATE SPECIFIC ANTIGEN; THYMINE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; CANCER GROWTH; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA POLYMORPHISM; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; START CODON;

BASE SEQUENCE; CODON, INITIATOR; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL;

EID: 12244254442     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Shibata, A., and Whittemore, A. S. Re: Prostate cancer incidence and mortality in the United States and the United Kingdom. J. Natl. Cancer Inst. (Bethesda), 93: 1109-1110, 2001.
2. Abbas, F., and Scardino, P. T. The natural history of clinical prostate carcinoma. Cancer (Phila.), 80: 827-833, 1997.
3. Boccon-Gibod, L. Significant versus insignificant prostate cancer: can we identify the tigers from the pussy cats? J. Urol., 156: 1069-1070, 1996.
4. Montie, J. E., and Meyers, S. E. Defining the ideal tumor marker for prostate cancer. Urol. Clin. N. Am., 24: 247-252, 1997.
5. Feldman, D., Malloy, P. J., and Gross, C. Vitamin D: biology, action and clinical implications. In: R. Marcus, D. Feldman, and J. Kelsey (eds.), Osteoporosis 1, pp. 257-304. San Diego, CA: Academic Press, 2001.
6. Malloy, P. J., Pike, J. W., and Feldman, D. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr. Rev., 20: 156-188, 1999.
7. Peehl, D. M., Skowronski, R. J., Leung, G. K., Wong, S. T., Stamey, T. A., and Feldman, D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res, 54: 805-810, 1994.
8. 3 receptors and actions in human prostate cancer cell lines. Endocrinology, 132: 1952-1960, 1993.
9. Zmuda, J. M., Cauley, J. A., and Ferrell, R. E. Molecular epidemiology of vitamin D receptor gene variants. Epidemiol. Rev., 22: 203-217, 2000.
10. Gross, C., Eccleshall, T. R., Malloy, P. J., Villa, M. L., Marcus, R., and Feldman, D. The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J. Bone Miner. Res., 11: 1850-1855, 1996.
11. Gross, C., Krishnan, A. V., Malloy, P. J., Eccleshall, T. R., Zhao, X. Y., and Feldman, D. The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. J. Bone Miner. Res., 13: 1691-1699, 1998.
12. Jurutka, P. W., Remus, L. S., Whitfield, G. K., Thompson, P. D., Hsieh, J. C., Zitzer, H., Tavakkoli, P., Galligan, M. A., Dang, H. T., Haussler, C. A., and Haussler, M. R. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol. Endocrinol., 14: 401-420, 2000.
13. Whitfield, G. K., Remus, L. S., Jurutka, P. W., Zitzer, H., Oza, A. K., Dang, H. T., Haussler, C. A., Galligan, M. A., Thatcher, M. L., Encinas Dominguez, C., and Haussler, M. R. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol. Cell. Endocrinol., 177: 145-159, 2001.
14. Hutchinson, P. E., Osborne, J. E., Lear, J. T., Smith, A. G., Bowers, P. W., Morris, P. N., Jones, P. W., York, C., Strange, R. C., and Fryer, A. A. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin. Cancer Res., 6: 498-504, 2000.
15. Ingles, S. A., Wang, J., Coetzee, G. A., Lee, E. R., Frankl, H. D., and Haile, R. W. Vitamin D receptor polymorphisms and risk of colorectal adenomas (United States). Cancer Causes Control, 12: 607-614, 2001.
16. Luscombe, C. J., French, M. E., Liu, S., Saxby, M. F., Jones, P. W., Fryer, A. A., and Strange, R. C. Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br. J. Cancer, 85: 1504-1509, 2001.
17. Chokkalingam, A. P., McGlynn, K. A., Gao, Y. T., Pollak, M., Deng, J., Sesterhenn, I. A., Mostofi, F. K., Fraumeni, J. F., Jr., and Hsing, A. W. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. Cancer Res., 61: 4333-4336, 2001.
18. Ingles, S. A., Coetzee, G. A., Ross, R. K., Henderson, B. E., Kolonel, L. N., Crocitto, L., Wang, W., and Haile, R. W. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res., 58: 1620-1623, 1998.
19. Taylor, J. A., Hirvonen, A., Watson, M., Pittman, G., Mohler, J. L., and Bell, D. A. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res., 56: 4108-4110, 1996.
20. Ingles, S. A., Ross, R. K., Yu, M. C., Irvine, R. A., La Pera, G., Haile, R. W., and Coetzee, G. A. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst. (Bethesda), 89: 166-170, 1997.
21. Habuchi, T., Suzuki, T., Sasaki, R., Wang, L., Sato, K., Satoh, S., Akao, T., Tsuchiya, N., Shimoda, N., Wada, Y., Koizumi, A., Chihara, J., Ogawa, O., and Kato, T. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res., 60: 305-308, 2000.
22. Ma, J., Stampfer, M. J., Gann, P. H., Hough, H. L., Giovannucci, E., Kelsey, K. T., Hennekens, C. H., and Hunter. D. J. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol. Biomark. Prev., 7: 385-390, 1998.
23. Kibel, A. S., Isaacs, S D., Isaacs, W. B., and Bova, G. S. Vitamin D receptor polymorphisms and lethal prostate cancer. J. Urol., 160: 1405-1409, 1998.
24. Watanabe, M., Fukutome, K., Murata, M., Uemura, H., Kubota, Y., Kawamura, J., and Yatani, R. Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese. Anticancer Res., 19: 4511-4514, 1999.
25. Blazer, D. G., III, Umbach, D. M., Bostick, R. M., and Taylor, J. A. Vitamin D receptor polymorphisms and prostate cancer. Mol. Carcinog., 27: 18-23, 2000.
26. Gsur, A., Madersbacher, S., Haidinger, G., Schatzl, G., Marberger, M., Vutuc, C., and Micksche, M. Vitamin D receptor gene polymorphism and prostate cancer risk. Prostate, 51: 30-34, 2002.
27. Konety, B. R., Johnson, C. S., Trump, D. L., and Getzenberg, R. H. Vitamin D in the prevention and treatment of prostate cancer. Semin. Urol. Oncol., 17: 77-84, 1999.
28. Blutt, S. E., and Weigel, N. L. Vitamin D and prostate cancer. Proc. Soc. Exp. Biol. Med., 221: 89-98, 1999.
29. Miller, G. J. Vitamin D and prostate cancer: biologic interactions and clinical potentials. Cancer Metastisis Rev., 17: 353-360, 1998.
30. Feldman, D., Zhao, X. Y., and Krishnan, A. V. Vitamin D and prostate cancer. Endocrinology, 141: 5-9, 2000.
31. Stamey, T. A., McNeal, J. E., Yemoto, C. M., Sigal, B. M., and Johnstone, I. M. Biological determinants of cancer progression in men with prostate cancer. J. Am. Med. Assoc., 281: 1395-1400, 1999.
32. Stamey, T. A., Yemoto, C. M., McNeal, J. E., Sigal, B. M., and Johnstone, I. M. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J. Urol., 163: 1155-1160, 2000.
33. Stamey, T. A., McNeal, J. E., Freiha, F. S., and Redwine, E. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J. Urol., 139: 1235-1241, 1988.
34. McNeal, J. E., Villers, A. A., Redwine, E. A., Freiha, F. S., and Stamey, T. A. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer (Phila.), 66: 1225-1233, 1990.
35. Gleason, D. F., and Mellinger, G. T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol., 111: 58-64, 1974.
36. Shibata, A., Garcia, M. I., Cheng, I., Stamey, T. A., McNeal, J. E., Brooks, J. D., Henderson, S., Yemoto, C. E., and Peehl, D. M. Polymorphisms in the androgen receptor and type II 5 a-reductase genes and prostate cancer prognosis. Prostate, 52: 269-278, 2002.
37. Harris, S. S., Eccleshall, T. R., Gross, C., Dawson-Hughes, B., and Feldman, D. The vitamin D receptor start codon polymorphism (FokI) and bone mineral density in premenopausal American black and white women. J. Bone Miner. Res., 12: 1043-1048, 1997.
38. SAS Institute Inc. The GLM procedure. In: SAS/STAT User's Guide, pp. 549-640. Cary, NC: SAS Institute Inc., 1988.
39. Rosner, B. Fundamentals of Biostatistic. Boston: PWS-Kent Publishing Company, 1990.
40. SAS Institute Inc. The PHREG procedure. In: SAS/STAT Software: Changes and Enhancements through Release 6.12, pp. 873-948. Cary, NC: SAS Institute Inc., 1997.
41. 3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res., 1: 997-1003, 1995.
42. Luscombe, C. J., French, M. E., Liu, S., Saxby, M. F., Jones, P. W., Fryer, A. A., and Strange, R. C. Outcome in prostate cancer associations with skin type and polymorphism in pigmentation-related genes. Carcinogenesis (Lond.), 22: 1343-1347, 2001.
43. Carroll, P., Coley, C., McLeod, D., Schellhammer, P., Sweat, G., Wasson, J., Zietman, A., and Thompson, I. Prostate-specific antigen best practice policy. Part II: prostate cancer staging and post-treatment follow-up. Urology, 57: 225-229, 2001.
44. Pound, C. R., Partin, A. W., Eisenberger, M. A., Chan, D. W., Pearson, J. D., and Walsh, P. C. Natural history of progression after PSA elevation following radical prostatectomy. J. Am. Med. Assoc., 281: 1591-1597, 1999.
45. Fischer, P. R., Thacher, T. D., Pettifor, J. M., Jorde, L. B., Eccleshall, T. R., and Feldman, D. Vitamin D receptor polymorphisms and nutritional rickets in Nigerian children. J. Bone Miner. Res., 15: 2206-2210, 2000.